Cipla Limited has announced the launch of Cippoint, a point-ofcare testing device.
As per the regulatory filing, this state-of-the-art device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device is CE IVD approved – indicating the device is approved by the European In-Vitro Diagnostic Device Directive, thus ensuring reliable testing solutions.
With entry in these new segments, Cipla has expanded its product offerings for diagnostics laboratories and aims to bridge the current gap in the diagnostic ecosystem in India by providing reliable and accurate tests at affordable prices.
Cippoint is an immunofluorescence based quantitative analyser that will allow healthcare professionals to get test results in 3 to 15 minutes, thus enabling a faster clinical decision-making process. Cippoint has an automated system and user-friendly interface which can be used even in rural areas, mobile vans, and remote areas with limited infrastructure.
Cippoint aims to enable smaller healthcare establishments provide an accurate point-of-care testing experience, ultimately improving patient health outcomes, the company said.
At around 3:00 PM, Cipla was trading at Rs1061.85 per share lower by 0.66% on the BSE.
For feedback and suggestions, write to us at editorial@iifl.com
